Characterization of βARKct engineered cellular extracellular vesicles and model specific cardioprotection

Am J Physiol Heart Circ Physiol. 2021 Apr 1;320(4):H1276-H1289. doi: 10.1152/ajpheart.00571.2020. Epub 2021 Jan 29.

Abstract

Recent data supporting any benefit of stem cell therapy for ischemic heart disease have suggested paracrine-based mechanisms via extracellular vesicles (EVs) including exosomes. We have previously engineered cardiac-derived progenitor cells (CDCs) to express a peptide inhibitor, βARKct, of G protein-coupled receptor kinase 2, leading to improvements in cell proliferation, survival, and metabolism. In this study, we tested whether βARKct-CDC EVs would be efficacious when applied to stressed myocytes in vitro and in vivo. When isolated EVs from βARKct-CDCs and control GFP-CDCs were added to cardiomyocytes in culture, they both protected against hypoxia-induced apoptosis. We tested whether these EVs could protect the mouse heart in vivo, following exposure either to myocardial infarction (MI) or acute catecholamine toxicity. Both types of EVs significantly protected against ischemic injury and improved cardiac function after MI compared with mice treated with EVs from mouse embryonic fibroblasts; however, βARKct EVs treated mice did display some unique beneficial properties including significantly altered pro- and anti-inflammatory cytokines. Importantly, in a catecholamine toxicity model of heart failure (HF), myocardial injections of βARKct-containing EVs were superior at preventing HF compared with control EVs, and this catecholamine toxicity protection was recapitulated in vitro. Therefore, introduction of the βARKct into cellular EVs can have improved reparative properties in the heart especially against catecholamine damage, which is significant as sympathetic nervous system activity is increased in HF.NEW & NOTEWORTHY βARKct, the peptide inhibitor of GRK2, improves survival and metabolic functions of cardiac-derived progenitor cells. As any benefit of stem cells in the ischemic and injured heart suggests paracrine mechanisms via secreted EVs, we investigated whether CDC-βARKct engineered EVs would show any benefit over control CDC-EVs. Compared with control EVs, βARKct-containing EVs displayed some unique beneficial properties that may be due to altered pro- and anti-inflammatory cytokines within the vesicles.

Keywords: GRK2; cardiac derived cells; cardiomyocytes; extracellular vesicles; microRNAs; βARKct.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Apoptosis
  • Cell Hypoxia
  • Cells, Cultured
  • Cytokines / genetics
  • Cytokines / metabolism
  • Disease Models, Animal
  • Extracellular Vesicles / genetics
  • Extracellular Vesicles / metabolism
  • Extracellular Vesicles / transplantation*
  • G-Protein-Coupled Receptor Kinase 2 / metabolism
  • Heart Failure / genetics
  • Heart Failure / metabolism
  • Heart Failure / physiopathology
  • Heart Failure / prevention & control*
  • Inflammation Mediators / metabolism
  • Male
  • Mice
  • Mice, Inbred C57BL
  • MicroRNAs / genetics
  • MicroRNAs / metabolism
  • Myocardial Infarction / genetics
  • Myocardial Infarction / metabolism
  • Myocardial Infarction / physiopathology
  • Myocardial Infarction / prevention & control*
  • Myocytes, Cardiac / metabolism*
  • Myocytes, Cardiac / pathology
  • Paracrine Communication
  • Peptides / genetics
  • Peptides / metabolism*
  • Rats
  • Recombinant Proteins / genetics
  • Recombinant Proteins / metabolism*
  • Recovery of Function
  • Signal Transduction
  • Stem Cell Transplantation*
  • Stem Cells / metabolism

Substances

  • Cytokines
  • Inflammation Mediators
  • MicroRNAs
  • Peptides
  • Recombinant Proteins
  • beta-adrenergic receptor kinase inhibitory peptide
  • GRK2 protein, mouse
  • G-Protein-Coupled Receptor Kinase 2